Contineum Therapeutics, Inc.
CTNMNASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $314.54M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $6.73$17.79
- Volume (live)
- -
- Avg. volume (3M)
- 1.21M
Contineum Therapeutics (CTNM) Stock Price & Financial Analysis
Contineum Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $8.12 - $8.75 |
|---|---|
| 52-Week High | $17.79 |
| 52-Week Low | $6.73 |
| Open | $8.32 |
| Volume (last close) | 498.75K |
| Average Volume (3M) | 1.21M |
| 50-Day MA | $13.71 |
|---|---|
| 200-Day MA | $13.60 |
| 1-Year Change | −24.51% |
| Market Cap | 314.54M |
|---|---|
| Shares Outstanding | 37.47M |
| Price to Book (P/B) | 1.31 |
| EV/EBITDA | -4.64 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Contineum Therapeutics at a Glance
As of the Oct 22, 2026 close, Contineum Therapeutics (CTNM) has a market capitalization of $314.54M.
As of its latest reported balance sheet, it holds $14.71M in cash and securities against $6.57M of debt, a net cash position of $8.14M.
Contineum Therapeutics does not currently pay a dividend.
The share price is down 24.5% over the past year. At $8.39 (the Oct 22, 2026 close) it sits within its 52-week range of $6.72 to $17.79, below its 200-day moving average of $13.60.
Based on 8 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $22.14, 163.7% above the Oct 22, 2026 close.
Frequently Asked Questions About Contineum Therapeutics
What is the current stock price for CTNM?
As of the Oct 22, 2026 close, CTNM stock trades at $8.39. The 52-week range is $6.73–$17.79, with a day range of $8.12–$8.75.
What is the P/E ratio for CTNM?
The P/E ratio (Price-to-Earnings) for CTNM is shown in the Key Statistics section. This valuation metric helps compare Contineum Therapeutics, Inc. to industry peers.
Does CTNM pay dividends?
Contineum Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for CTNM?
Based on ratings from 8 professional analysts over the last 90 days, the consensus for CTNM is Buy. The average 12-month price target is $22.14, a 163.7% upside from the Oct 22, 2026 close of $8.39.
What is the market cap of CTNM?
As of the Oct 22, 2026 close, Contineum Therapeutics's market capitalization is $314.5M, classifying it as a small-cap company. Contineum Therapeutics operates in the Healthcare sector within the Biotechnology industry.